Read More Pharma Industry News ImmunityBio (NASDAQ: IBRX) secures Saudi FDA approval for ANKTIVA in BCG-unresponsive bladder cancer ImmunityBio secures Saudi approval for ANKTIVA in NMIBC. Find out how this reshapes the company’s MENA strategy and immunotherapy ambitions. byPallavi MadhirajuJanuary 15, 2026